| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Congenital Hypothyroidism | 14 | 2023 | 79 | 5.590 |
Why?
|
| Thyroid Hormones | 55 | 2020 | 321 | 5.160 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 33 | 2020 | 116 | 4.480 |
Why?
|
| Receptors, Thyroid Hormone | 36 | 2011 | 159 | 3.510 |
Why?
|
| Thyroid Gland | 28 | 2017 | 270 | 2.950 |
Why?
|
| Iodide Peroxidase | 12 | 2023 | 203 | 2.890 |
Why?
|
| Thyroid Hormone Receptors beta | 21 | 2017 | 81 | 2.750 |
Why?
|
| Thyroxine | 42 | 2021 | 344 | 2.730 |
Why?
|
| Mutation | 43 | 2023 | 3978 | 2.440 |
Why?
|
| Triiodothyronine | 45 | 2021 | 339 | 2.410 |
Why?
|
| Thyrotropin | 49 | 2020 | 280 | 2.280 |
Why?
|
| Iron-Binding Proteins | 3 | 2021 | 15 | 2.200 |
Why?
|
| Thyroglobulin | 6 | 2020 | 59 | 2.200 |
Why?
|
| Thyroid Hormone Receptors alpha | 12 | 2020 | 22 | 2.090 |
Why?
|
| Autoantigens | 3 | 2021 | 127 | 2.060 |
Why?
|
| Mutation, Missense | 6 | 2020 | 276 | 1.890 |
Why?
|
| Symporters | 17 | 2021 | 105 | 1.400 |
Why?
|
| Pedigree | 43 | 2020 | 965 | 1.390 |
Why?
|
| Thyroid Diseases | 12 | 2020 | 104 | 1.290 |
Why?
|
| Thyroid Function Tests | 26 | 2021 | 119 | 1.260 |
Why?
|
| Heterozygote | 10 | 2021 | 366 | 1.240 |
Why?
|
| Transcription Factors | 14 | 2009 | 1580 | 1.230 |
Why?
|
| Pituitary Gland | 13 | 2012 | 117 | 1.180 |
Why?
|
| Adrenocorticotropic Hormone | 8 | 2012 | 131 | 1.150 |
Why?
|
| Membrane Transport Proteins | 10 | 2017 | 166 | 1.020 |
Why?
|
| Muscle Hypotonia | 6 | 2021 | 45 | 0.980 |
Why?
|
| Mice, Knockout | 34 | 2017 | 1944 | 0.910 |
Why?
|
| Phenotype | 22 | 2021 | 2389 | 0.910 |
Why?
|
| Awards and Prizes | 1 | 2023 | 36 | 0.900 |
Why?
|
| Male | 108 | 2021 | 40654 | 0.870 |
Why?
|
| Thyrotropin, beta Subunit | 3 | 2020 | 10 | 0.860 |
Why?
|
| Dual Oxidases | 2 | 2020 | 14 | 0.860 |
Why?
|
| Liver | 16 | 2015 | 1229 | 0.820 |
Why?
|
| Histone Acetyltransferases | 10 | 2009 | 38 | 0.810 |
Why?
|
| Point Mutation | 14 | 2012 | 246 | 0.800 |
Why?
|
| Humans | 136 | 2023 | 85796 | 0.800 |
Why?
|
| Monocarboxylic Acid Transporters | 14 | 2021 | 79 | 0.800 |
Why?
|
| Biological Products | 1 | 2023 | 143 | 0.790 |
Why?
|
| Pituitary ACTH Hypersecretion | 5 | 2012 | 11 | 0.790 |
Why?
|
| Muscular Atrophy | 5 | 2021 | 41 | 0.790 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 2011 | 81 | 0.760 |
Why?
|
| Female | 89 | 2021 | 44218 | 0.750 |
Why?
|
| Hyperthyroidism | 7 | 2017 | 75 | 0.740 |
Why?
|
| Alu Elements | 1 | 2020 | 15 | 0.720 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 7 | 2003 | 184 | 0.720 |
Why?
|
| Mutagenesis, Insertional | 1 | 2020 | 111 | 0.690 |
Why?
|
| Hypothyroidism | 15 | 2013 | 232 | 0.660 |
Why?
|
| Hydrocortisone | 6 | 2006 | 300 | 0.660 |
Why?
|
| Protein Multimerization | 1 | 2020 | 173 | 0.650 |
Why?
|
| DNA-Binding Proteins | 5 | 2021 | 1214 | 0.630 |
Why?
|
| Adrenal Glands | 3 | 2006 | 76 | 0.630 |
Why?
|
| Mental Retardation, X-Linked | 4 | 2021 | 21 | 0.620 |
Why?
|
| Child | 30 | 2020 | 6930 | 0.610 |
Why?
|
| Energy Metabolism | 5 | 2015 | 272 | 0.590 |
Why?
|
| Mice | 46 | 2017 | 11439 | 0.580 |
Why?
|
| Goiter | 5 | 2018 | 43 | 0.570 |
Why?
|
| Nuclear Receptor Coactivator 1 | 10 | 2009 | 24 | 0.570 |
Why?
|
| Child, Preschool | 17 | 2020 | 3612 | 0.560 |
Why?
|
| Animals | 67 | 2017 | 26652 | 0.550 |
Why?
|
| Prenatal Diagnosis | 3 | 2017 | 104 | 0.540 |
Why?
|
| Pituitary Neoplasms | 3 | 2006 | 62 | 0.530 |
Why?
|
| Pregnancy | 15 | 2020 | 2899 | 0.530 |
Why?
|
| Sudan | 3 | 2020 | 13 | 0.520 |
Why?
|
| Serum Albumin | 5 | 2014 | 128 | 0.520 |
Why?
|
| Adipose Tissue | 2 | 2014 | 241 | 0.500 |
Why?
|
| Adenoma | 3 | 2007 | 236 | 0.490 |
Why?
|
| Trans-Activators | 6 | 2006 | 430 | 0.490 |
Why?
|
| Adult | 45 | 2021 | 25522 | 0.490 |
Why?
|
| Genotype | 18 | 2018 | 1848 | 0.490 |
Why?
|
| Gene Expression Regulation | 10 | 2013 | 1928 | 0.480 |
Why?
|
| Repressor Proteins | 3 | 2006 | 405 | 0.470 |
Why?
|
| Nuclear Proteins | 5 | 2006 | 707 | 0.460 |
Why?
|
| Diiodothyronines | 4 | 2015 | 12 | 0.450 |
Why?
|
| Propionates | 4 | 2015 | 34 | 0.450 |
Why?
|
| Receptors, Thyrotropin | 4 | 2007 | 47 | 0.450 |
Why?
|
| Steroids | 1 | 2014 | 175 | 0.440 |
Why?
|
| Thyrotoxicosis | 3 | 2004 | 18 | 0.410 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2011 | 31 | 0.410 |
Why?
|
| Infant, Newborn | 10 | 2021 | 2381 | 0.410 |
Why?
|
| Hyperthyroxinemia | 5 | 2001 | 17 | 0.400 |
Why?
|
| Models, Biological | 2 | 2014 | 1749 | 0.390 |
Why?
|
| Infant | 7 | 2020 | 3051 | 0.390 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2015 | 882 | 0.390 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 60 | 0.390 |
Why?
|
| Triiodothyronine, Reverse | 8 | 2021 | 32 | 0.390 |
Why?
|
| Adolescent | 20 | 2020 | 8959 | 0.380 |
Why?
|
| Cushing Syndrome | 4 | 2007 | 24 | 0.380 |
Why?
|
| Feedback, Physiological | 2 | 2007 | 62 | 0.370 |
Why?
|
| Fibroblasts | 5 | 2009 | 731 | 0.360 |
Why?
|
| RNA-Binding Proteins | 4 | 2020 | 251 | 0.360 |
Why?
|
| Aldosterone | 3 | 2006 | 56 | 0.360 |
Why?
|
| Iodine Radioisotopes | 3 | 2013 | 134 | 0.350 |
Why?
|
| Serum | 1 | 2009 | 25 | 0.340 |
Why?
|
| Pregnancy Complications | 3 | 2017 | 337 | 0.330 |
Why?
|
| Bone and Bones | 7 | 2017 | 264 | 0.330 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 977 | 0.330 |
Why?
|
| Thyroidectomy | 1 | 2009 | 170 | 0.320 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 728 | 0.320 |
Why?
|
| Homozygote | 6 | 2018 | 200 | 0.310 |
Why?
|
| Human Growth Hormone | 4 | 2013 | 54 | 0.310 |
Why?
|
| Mothers | 2 | 2017 | 142 | 0.310 |
Why?
|
| Heart | 3 | 2002 | 556 | 0.310 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2007 | 2 | 0.310 |
Why?
|
| Prostatic Neoplasms | 6 | 2001 | 1721 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 12 | 2017 | 3112 | 0.300 |
Why?
|
| Amino Acid Substitution | 7 | 2020 | 339 | 0.300 |
Why?
|
| Frameshift Mutation | 3 | 2006 | 51 | 0.300 |
Why?
|
| Antithyroid Agents | 3 | 2020 | 20 | 0.290 |
Why?
|
| Prolactin | 2 | 2006 | 88 | 0.290 |
Why?
|
| Syndrome | 9 | 2010 | 445 | 0.290 |
Why?
|
| Drug Resistance | 10 | 2006 | 232 | 0.280 |
Why?
|
| Prolactinoma | 1 | 2006 | 8 | 0.280 |
Why?
|
| Skin | 2 | 2009 | 554 | 0.280 |
Why?
|
| Obesity | 3 | 2008 | 943 | 0.280 |
Why?
|
| Saliva | 1 | 2006 | 123 | 0.260 |
Why?
|
| Genetic Linkage | 8 | 2008 | 623 | 0.260 |
Why?
|
| Middle Aged | 28 | 2018 | 24742 | 0.260 |
Why?
|
| Lung | 1 | 2011 | 1181 | 0.260 |
Why?
|
| Addison Disease | 2 | 2002 | 4 | 0.260 |
Why?
|
| Prealbumin | 2 | 2012 | 34 | 0.250 |
Why?
|
| Palpation | 2 | 2001 | 18 | 0.250 |
Why?
|
| Base Sequence | 20 | 2006 | 2334 | 0.250 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 73 | 0.250 |
Why?
|
| Cerebellum | 1 | 2006 | 247 | 0.240 |
Why?
|
| RNA, Messenger | 9 | 2011 | 1987 | 0.240 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 3 | 2011 | 23 | 0.240 |
Why?
|
| Receptors, Steroid | 2 | 2006 | 42 | 0.240 |
Why?
|
| Early Diagnosis | 2 | 2021 | 121 | 0.230 |
Why?
|
| Circadian Rhythm | 2 | 2004 | 294 | 0.230 |
Why?
|
| Diiodotyrosine | 1 | 2023 | 3 | 0.230 |
Why?
|
| Empty Sella Syndrome | 1 | 2003 | 1 | 0.230 |
Why?
|
| Drug Approval | 1 | 2023 | 62 | 0.220 |
Why?
|
| Bone Development | 5 | 2017 | 35 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 2271 | 0.220 |
Why?
|
| United States Food and Drug Administration | 1 | 2023 | 126 | 0.220 |
Why?
|
| Pituitary Hormones | 1 | 2002 | 7 | 0.220 |
Why?
|
| Adrenocortical Hyperfunction | 1 | 2002 | 6 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 5 | 2011 | 943 | 0.220 |
Why?
|
| Orchitis | 1 | 2002 | 10 | 0.220 |
Why?
|
| Epididymitis | 1 | 2002 | 5 | 0.220 |
Why?
|
| Propylthiouracil | 3 | 2020 | 24 | 0.220 |
Why?
|
| Adrenal Insufficiency | 1 | 2002 | 23 | 0.220 |
Why?
|
| Aging | 3 | 2008 | 689 | 0.220 |
Why?
|
| Thyroid Nodule | 2 | 2007 | 51 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 9 | 2011 | 929 | 0.210 |
Why?
|
| Terminology as Topic | 2 | 2014 | 215 | 0.210 |
Why?
|
| Diagnosis, Differential | 8 | 2008 | 1561 | 0.210 |
Why?
|
| Acromegaly | 1 | 2002 | 5 | 0.210 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 90 | 0.210 |
Why?
|
| Molecular Sequence Data | 14 | 2006 | 3034 | 0.210 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 337 | 0.210 |
Why?
|
| Dried Blood Spot Testing | 1 | 2021 | 10 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 853 | 0.190 |
Why?
|
| Thyrotropin-Releasing Hormone | 5 | 2005 | 40 | 0.190 |
Why?
|
| Early Medical Intervention | 1 | 2020 | 18 | 0.190 |
Why?
|
| Tuberculosis | 1 | 2002 | 110 | 0.190 |
Why?
|
| Fetal Therapies | 1 | 2020 | 5 | 0.190 |
Why?
|
| Family | 2 | 2020 | 311 | 0.190 |
Why?
|
| Megalencephaly | 1 | 2020 | 21 | 0.190 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2001 | 67 | 0.190 |
Why?
|
| Gene Expression | 7 | 2015 | 1286 | 0.190 |
Why?
|
| Neonatal Screening | 1 | 2021 | 59 | 0.190 |
Why?
|
| User-Computer Interface | 1 | 2001 | 185 | 0.190 |
Why?
|
| Osteogenesis | 5 | 2007 | 244 | 0.180 |
Why?
|
| Gene Frequency | 2 | 2020 | 677 | 0.180 |
Why?
|
| Urethral Neoplasms | 1 | 2000 | 10 | 0.180 |
Why?
|
| Penile Neoplasms | 1 | 2000 | 10 | 0.180 |
Why?
|
| Cells, Cultured | 7 | 2013 | 2836 | 0.180 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2017 | 76 | 0.180 |
Why?
|
| Constipation | 1 | 2020 | 62 | 0.180 |
Why?
|
| Selenoproteins | 1 | 2020 | 19 | 0.180 |
Why?
|
| Body Fluids | 1 | 2000 | 35 | 0.180 |
Why?
|
| Hormone Replacement Therapy | 3 | 2013 | 77 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2020 | 3366 | 0.180 |
Why?
|
| Family Health | 2 | 2018 | 162 | 0.180 |
Why?
|
| Protein Isoforms | 5 | 2004 | 272 | 0.170 |
Why?
|
| Nuclear Receptor Coactivator 3 | 3 | 2004 | 5 | 0.170 |
Why?
|
| Multigene Family | 2 | 1999 | 202 | 0.170 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 1999 | 33 | 0.170 |
Why?
|
| Behcet Syndrome | 1 | 1999 | 13 | 0.170 |
Why?
|
| Animals, Newborn | 4 | 2014 | 516 | 0.170 |
Why?
|
| Heart Aneurysm | 1 | 1999 | 22 | 0.170 |
Why?
|
| Phantoms, Imaging | 1 | 2001 | 429 | 0.170 |
Why?
|
| Protein Domains | 1 | 2020 | 128 | 0.170 |
Why?
|
| Aneurysm, Ruptured | 1 | 1999 | 51 | 0.170 |
Why?
|
| Renal Artery | 1 | 1999 | 50 | 0.170 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 195 | 0.170 |
Why?
|
| Cysts | 1 | 2000 | 104 | 0.170 |
Why?
|
| Aneurysm, False | 1 | 1999 | 54 | 0.170 |
Why?
|
| Brain | 7 | 2020 | 2219 | 0.170 |
Why?
|
| Nuclear Receptor Coactivator 2 | 3 | 2003 | 15 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2001 | 333 | 0.170 |
Why?
|
| Haplotypes | 8 | 2015 | 639 | 0.160 |
Why?
|
| Bayes Theorem | 2 | 2001 | 360 | 0.160 |
Why?
|
| Radionuclide Imaging | 3 | 2006 | 220 | 0.160 |
Why?
|
| Germinoma | 1 | 1998 | 3 | 0.160 |
Why?
|
| Pregnancy Outcome | 3 | 2017 | 247 | 0.160 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 294 | 0.160 |
Why?
|
| Cognition | 1 | 2003 | 570 | 0.160 |
Why?
|
| Prevalence | 2 | 2020 | 1210 | 0.160 |
Why?
|
| Biomarkers | 2 | 2021 | 1697 | 0.160 |
Why?
|
| Exome | 1 | 2018 | 127 | 0.160 |
Why?
|
| Australia | 1 | 2018 | 99 | 0.160 |
Why?
|
| Sodium | 2 | 1991 | 328 | 0.160 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1998 | 43 | 0.160 |
Why?
|
| Rats | 12 | 2013 | 3998 | 0.160 |
Why?
|
| Insulin Resistance | 2 | 2013 | 359 | 0.160 |
Why?
|
| Cattle | 2 | 2009 | 376 | 0.160 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 215 | 0.160 |
Why?
|
| Amino Acid Sequence | 6 | 2007 | 2065 | 0.150 |
Why?
|
| Research | 2 | 2014 | 251 | 0.150 |
Why?
|
| Neoplasm Staging | 2 | 2000 | 1938 | 0.150 |
Why?
|
| Aged | 16 | 2013 | 18161 | 0.150 |
Why?
|
| Autoantibodies | 3 | 2010 | 267 | 0.150 |
Why?
|
| Fetal Diseases | 1 | 2017 | 82 | 0.150 |
Why?
|
| Heart Failure | 1 | 2006 | 1136 | 0.150 |
Why?
|
| Leeches | 1 | 1996 | 5 | 0.150 |
Why?
|
| Amputation, Traumatic | 1 | 1996 | 9 | 0.150 |
Why?
|
| Testicular Neoplasms | 1 | 1998 | 105 | 0.150 |
Why?
|
| Growth | 1 | 1996 | 43 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 551 | 0.140 |
Why?
|
| Replantation | 1 | 1996 | 36 | 0.140 |
Why?
|
| Mice, Inbred Strains | 2 | 2011 | 307 | 0.140 |
Why?
|
| Cell Differentiation | 6 | 2007 | 1471 | 0.140 |
Why?
|
| Penis | 1 | 1996 | 56 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2000 | 533 | 0.140 |
Why?
|
| Cartilage | 3 | 1981 | 113 | 0.140 |
Why?
|
| Cholesterol | 6 | 2006 | 353 | 0.140 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 2 | 2006 | 23 | 0.140 |
Why?
|
| Protein Folding | 1 | 2018 | 282 | 0.140 |
Why?
|
| Fibronectins | 3 | 1981 | 98 | 0.140 |
Why?
|
| Heart Rate | 4 | 2002 | 478 | 0.130 |
Why?
|
| Melanoma | 1 | 2000 | 459 | 0.130 |
Why?
|
| Young Adult | 5 | 2020 | 5961 | 0.130 |
Why?
|
| United States | 3 | 2023 | 6582 | 0.130 |
Why?
|
| Muscle, Skeletal | 4 | 2015 | 450 | 0.130 |
Why?
|
| Quality of Life | 4 | 2010 | 1581 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 1760 | 0.130 |
Why?
|
| DNA, Complementary | 7 | 2008 | 394 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 1998 | 252 | 0.130 |
Why?
|
| Transgender Persons | 1 | 2017 | 95 | 0.130 |
Why?
|
| Sleep | 2 | 2013 | 441 | 0.130 |
Why?
|
| Thyroxine-Binding Globulin | 1 | 2015 | 6 | 0.130 |
Why?
|
| DNA | 11 | 2006 | 1294 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1995 | 78 | 0.130 |
Why?
|
| Intellectual Disability | 3 | 1999 | 186 | 0.130 |
Why?
|
| Birth Weight | 3 | 2017 | 145 | 0.130 |
Why?
|
| Mice, Transgenic | 4 | 2009 | 1557 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 4 | 2011 | 1060 | 0.120 |
Why?
|
| Placenta | 2 | 2014 | 176 | 0.120 |
Why?
|
| Hyperthyroxinemia, Familial Dysalbuminemic | 1 | 2014 | 8 | 0.120 |
Why?
|
| Carbohydrate Metabolism | 1 | 2014 | 29 | 0.120 |
Why?
|
| Carrier Proteins | 3 | 2006 | 675 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 275 | 0.120 |
Why?
|
| Academies and Institutes | 1 | 2014 | 31 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 4 | 2001 | 353 | 0.120 |
Why?
|
| Research Support as Topic | 1 | 2014 | 80 | 0.120 |
Why?
|
| Research Personnel | 1 | 2014 | 67 | 0.120 |
Why?
|
| Metabolism, Inborn Errors | 1 | 1993 | 30 | 0.110 |
Why?
|
| Muscles | 2 | 1991 | 194 | 0.110 |
Why?
|
| Growth Disorders | 2 | 2012 | 63 | 0.110 |
Why?
|
| Hypopituitarism | 1 | 2013 | 19 | 0.110 |
Why?
|
| Acetates | 1 | 2013 | 65 | 0.110 |
Why?
|
| Phenols | 1 | 2013 | 40 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2014 | 112 | 0.110 |
Why?
|
| Universities | 1 | 2014 | 135 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 395 | 0.110 |
Why?
|
| Anilides | 1 | 2013 | 47 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 2354 | 0.110 |
Why?
|
| Growth and Development | 1 | 2012 | 12 | 0.110 |
Why?
|
| Brain Waves | 1 | 2013 | 32 | 0.110 |
Why?
|
| Glucocorticoids | 2 | 2014 | 350 | 0.110 |
Why?
|
| Selenium | 2 | 2010 | 44 | 0.110 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 197 | 0.110 |
Why?
|
| Thyroxine-Binding Proteins | 3 | 1998 | 86 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 269 | 0.110 |
Why?
|
| Sleep Wake Disorders | 3 | 2010 | 114 | 0.110 |
Why?
|
| Cell Nucleus | 3 | 2010 | 581 | 0.110 |
Why?
|
| Disease Progression | 2 | 2007 | 1458 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 4 | 1998 | 1041 | 0.110 |
Why?
|
| Pseudohypoparathyroidism | 1 | 1992 | 5 | 0.110 |
Why?
|
| Radioimmunoassay | 3 | 2010 | 155 | 0.100 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 158 | 0.100 |
Why?
|
| Cerebral Cortex | 2 | 2013 | 586 | 0.100 |
Why?
|
| Fatty Liver | 1 | 2013 | 123 | 0.100 |
Why?
|
| Iodine | 2 | 2013 | 43 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2017 | 153 | 0.100 |
Why?
|
| Transfection | 5 | 2006 | 899 | 0.100 |
Why?
|
| Thyroid Dysgenesis | 1 | 2011 | 9 | 0.100 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 55 | 0.100 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 1991 | 21 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 44 | 0.100 |
Why?
|
| Mice, Inbred DBA | 1 | 2011 | 149 | 0.100 |
Why?
|
| Orchiectomy | 2 | 2002 | 68 | 0.100 |
Why?
|
| Alternative Splicing | 2 | 2004 | 202 | 0.100 |
Why?
|
| Hyperinsulinism | 2 | 2013 | 47 | 0.100 |
Why?
|
| Chemokines | 1 | 2011 | 73 | 0.100 |
Why?
|
| Biopsy | 3 | 2007 | 1163 | 0.100 |
Why?
|
| Species Specificity | 2 | 2011 | 678 | 0.100 |
Why?
|
| Microsurgery | 1 | 2012 | 84 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 241 | 0.100 |
Why?
|
| Mice, Inbred C3H | 1 | 2011 | 371 | 0.100 |
Why?
|
| Chromosome Mapping | 4 | 2007 | 1073 | 0.100 |
Why?
|
| Osmolar Concentration | 3 | 2007 | 181 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 1998 | 1168 | 0.090 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 2010 | 3 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 2 | 2007 | 50 | 0.090 |
Why?
|
| Co-Repressor Proteins | 1 | 2010 | 18 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2011 | 694 | 0.090 |
Why?
|
| Sodium Channels | 1 | 1991 | 129 | 0.090 |
Why?
|
| Research Design | 1 | 2013 | 580 | 0.090 |
Why?
|
| Behavior | 2 | 2003 | 85 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 436 | 0.090 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 65 | 0.090 |
Why?
|
| Methimazole | 1 | 2009 | 13 | 0.090 |
Why?
|
| Hormones | 3 | 2010 | 140 | 0.090 |
Why?
|
| Phlebotomy | 1 | 2009 | 21 | 0.090 |
Why?
|
| Ultrasonography | 2 | 2002 | 692 | 0.090 |
Why?
|
| Time Factors | 8 | 2013 | 5178 | 0.090 |
Why?
|
| Culture Media | 1 | 2009 | 147 | 0.090 |
Why?
|
| RNA, Neoplasm | 1 | 2009 | 88 | 0.090 |
Why?
|
| Fatigue | 1 | 2010 | 174 | 0.080 |
Why?
|
| Body Height | 1 | 2009 | 99 | 0.080 |
Why?
|
| Alkaline Phosphatase | 4 | 2006 | 132 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2010 | 160 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 408 | 0.080 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2009 | 96 | 0.080 |
Why?
|
| Alleles | 4 | 2002 | 1128 | 0.080 |
Why?
|
| Genes, Dominant | 2 | 2005 | 117 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2006 | 4160 | 0.080 |
Why?
|
| Models, Animal | 2 | 2013 | 264 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2017 | 901 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 265 | 0.080 |
Why?
|
| Creatine Kinase | 2 | 2005 | 52 | 0.080 |
Why?
|
| Retrospective Studies | 9 | 2021 | 8466 | 0.080 |
Why?
|
| Weight-Bearing | 1 | 2008 | 61 | 0.080 |
Why?
|
| Lymph Node Excision | 2 | 2000 | 217 | 0.080 |
Why?
|
| Biological Transport | 3 | 2014 | 396 | 0.080 |
Why?
|
| Hypothalamus | 2 | 2006 | 79 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2009 | 235 | 0.080 |
Why?
|
| Random Allocation | 2 | 2017 | 330 | 0.080 |
Why?
|
| Hypophysectomy | 1 | 2007 | 27 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2001 | 1989 | 0.080 |
Why?
|
| Litter Size | 1 | 2007 | 12 | 0.080 |
Why?
|
| Rats, Inbred Dahl | 1 | 2007 | 8 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2010 | 1137 | 0.080 |
Why?
|
| Rats, Inbred BN | 1 | 2007 | 37 | 0.080 |
Why?
|
| Cytokines | 1 | 2011 | 781 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 692 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 2583 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2008 | 104 | 0.080 |
Why?
|
| Homeostasis | 2 | 2010 | 402 | 0.070 |
Why?
|
| Plasmids | 2 | 2006 | 292 | 0.070 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2010 | 147 | 0.070 |
Why?
|
| Chromosomes | 1 | 2007 | 96 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 738 | 0.070 |
Why?
|
| Receptor, Melanocortin, Type 2 | 1 | 2006 | 1 | 0.070 |
Why?
|
| Animals, Genetically Modified | 1 | 2007 | 182 | 0.070 |
Why?
|
| Oxidoreductases | 1 | 2007 | 112 | 0.070 |
Why?
|
| Risk Factors | 2 | 2014 | 5251 | 0.070 |
Why?
|
| Angiotensin II | 1 | 2006 | 91 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2006 | 148 | 0.070 |
Why?
|
| Introns | 1 | 2007 | 290 | 0.070 |
Why?
|
| Muscle Development | 1 | 1986 | 41 | 0.070 |
Why?
|
| Adrenalectomy | 1 | 2006 | 42 | 0.070 |
Why?
|
| Mosaicism | 1 | 2006 | 67 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2006 | 72 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2006 | 716 | 0.070 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2005 | 20 | 0.070 |
Why?
|
| Antioxidants | 1 | 2007 | 223 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2007 | 120 | 0.070 |
Why?
|
| Ferritins | 1 | 2005 | 29 | 0.070 |
Why?
|
| In Situ Hybridization | 3 | 2011 | 310 | 0.070 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2005 | 16 | 0.070 |
Why?
|
| Myocardium | 3 | 2003 | 550 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2006 | 271 | 0.070 |
Why?
|
| DNA Damage | 1 | 2007 | 366 | 0.060 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2004 | 12 | 0.060 |
Why?
|
| Body Temperature | 1 | 2005 | 124 | 0.060 |
Why?
|
| Cyclic AMP | 3 | 2011 | 273 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 486 | 0.060 |
Why?
|
| Ion Channels | 1 | 1986 | 245 | 0.060 |
Why?
|
| Pituitary-Adrenal System | 1 | 2004 | 64 | 0.060 |
Why?
|
| Bone Resorption | 2 | 2007 | 42 | 0.060 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2007 | 203 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2004 | 65 | 0.060 |
Why?
|
| Embryo, Mammalian | 3 | 2014 | 219 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2013 | 391 | 0.060 |
Why?
|
| 5' Untranslated Regions | 1 | 2004 | 49 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2004 | 283 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2007 | 272 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2004 | 29 | 0.060 |
Why?
|
| Abortion, Spontaneous | 1 | 2004 | 66 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2004 | 61 | 0.060 |
Why?
|
| Pituitary Gland, Anterior | 2 | 1999 | 22 | 0.060 |
Why?
|
| Monoiodotyrosine | 1 | 2023 | 4 | 0.060 |
Why?
|
| Pregnancy, Animal | 1 | 2003 | 58 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2004 | 174 | 0.060 |
Why?
|
| Florida | 1 | 2023 | 55 | 0.060 |
Why?
|
| Radiography | 2 | 2003 | 806 | 0.060 |
Why?
|
| Estradiol | 2 | 2002 | 251 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2001 | 2360 | 0.050 |
Why?
|
| Egypt | 1 | 2002 | 13 | 0.050 |
Why?
|
| Pulsatile Flow | 1 | 2002 | 49 | 0.050 |
Why?
|
| Genes, erbA | 2 | 2017 | 10 | 0.050 |
Why?
|
| Markov Chains | 2 | 2001 | 124 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2003 | 231 | 0.050 |
Why?
|
| Isoelectric Focusing | 1 | 2002 | 39 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2002 | 45 | 0.050 |
Why?
|
| Protein Biosynthesis | 2 | 2009 | 381 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 3591 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2000 | 1200 | 0.050 |
Why?
|
| Consanguinity | 2 | 1999 | 73 | 0.050 |
Why?
|
| Response Elements | 1 | 2002 | 63 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 21 | 0.050 |
Why?
|
| Leptin | 1 | 2002 | 104 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2013 | 7831 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 676 | 0.050 |
Why?
|
| Testis | 1 | 2002 | 152 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2002 | 52 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2001 | 832 | 0.050 |
Why?
|
| Albuminuria | 1 | 2001 | 48 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2003 | 216 | 0.050 |
Why?
|
| Calcitonin | 1 | 1981 | 38 | 0.050 |
Why?
|
| Weight Gain | 1 | 2002 | 121 | 0.050 |
Why?
|
| Age Factors | 2 | 2017 | 1828 | 0.050 |
Why?
|
| Chorionic Gonadotropin | 1 | 2001 | 72 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2002 | 226 | 0.050 |
Why?
|
| Psychometrics | 1 | 2003 | 327 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 114 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2002 | 207 | 0.050 |
Why?
|
| Albumins | 1 | 2001 | 129 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 234 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2001 | 16 | 0.050 |
Why?
|
| Retinoids | 1 | 2001 | 17 | 0.050 |
Why?
|
| Leukocytes | 1 | 2002 | 202 | 0.050 |
Why?
|
| Immunotherapy, Active | 1 | 2001 | 15 | 0.050 |
Why?
|
| Somatostatin | 1 | 1981 | 55 | 0.050 |
Why?
|
| Body Weight | 1 | 2002 | 451 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2002 | 261 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 502 | 0.050 |
Why?
|
| Amniotic Fluid | 1 | 2020 | 30 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2001 | 109 | 0.050 |
Why?
|
| Electrophysiology | 2 | 1991 | 401 | 0.050 |
Why?
|
| Interferons | 1 | 2001 | 133 | 0.050 |
Why?
|
| Affect | 1 | 2003 | 386 | 0.050 |
Why?
|
| Bone Matrix | 1 | 1980 | 18 | 0.050 |
Why?
|
| Urology | 1 | 2001 | 110 | 0.050 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2000 | 14 | 0.050 |
Why?
|
| Suction | 1 | 2000 | 35 | 0.050 |
Why?
|
| Needles | 1 | 2000 | 35 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2002 | 186 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 1981 | 253 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2010 | 135 | 0.040 |
Why?
|
| Membrane Potentials | 2 | 1991 | 435 | 0.040 |
Why?
|
| Urinary Diversion | 1 | 2000 | 42 | 0.040 |
Why?
|
| Forecasting | 1 | 2001 | 301 | 0.040 |
Why?
|
| Oxidation-Reduction | 2 | 2013 | 373 | 0.040 |
Why?
|
| Adipose Tissue, Brown | 2 | 2013 | 80 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2001 | 133 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2001 | 337 | 0.040 |
Why?
|
| Reference Values | 2 | 2010 | 663 | 0.040 |
Why?
|
| Tanzania | 1 | 1999 | 45 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 456 | 0.040 |
Why?
|
| Comorbidity | 1 | 2003 | 912 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 1999 | 57 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2000 | 109 | 0.040 |
Why?
|
| Testosterone | 1 | 2001 | 271 | 0.040 |
Why?
|
| Christianity | 1 | 1999 | 36 | 0.040 |
Why?
|
| Bone Marrow | 1 | 1981 | 435 | 0.040 |
Why?
|
| Tetrodotoxin | 2 | 1991 | 50 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 276 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2006 | 755 | 0.040 |
Why?
|
| Parathyroid Hormone | 1 | 2000 | 214 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 1999 | 185 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2001 | 244 | 0.040 |
Why?
|
| Osteoblasts | 3 | 2007 | 96 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 1999 | 251 | 0.040 |
Why?
|
| Collagen | 1 | 1980 | 273 | 0.040 |
Why?
|
| Rectum | 1 | 1999 | 146 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2000 | 310 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 818 | 0.040 |
Why?
|
| Exons | 3 | 1998 | 452 | 0.040 |
Why?
|
| Isotretinoin | 1 | 1997 | 23 | 0.040 |
Why?
|
| Pain Measurement | 1 | 1999 | 321 | 0.040 |
Why?
|
| Placental Circulation | 1 | 2017 | 11 | 0.040 |
Why?
|
| DNA Primers | 2 | 1999 | 545 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2017 | 70 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2011 | 787 | 0.040 |
Why?
|
| Kinetics | 3 | 2006 | 1513 | 0.040 |
Why?
|
| Fetal Development | 1 | 2017 | 30 | 0.040 |
Why?
|
| Chondrocytes | 1 | 2017 | 61 | 0.040 |
Why?
|
| Echocardiography | 1 | 2002 | 912 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 2017 | 38 | 0.040 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1996 | 7 | 0.040 |
Why?
|
| Adrenal Cortex Diseases | 1 | 1996 | 6 | 0.040 |
Why?
|
| COS Cells | 3 | 2004 | 166 | 0.040 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1996 | 30 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 2001 | 502 | 0.040 |
Why?
|
| Suramin | 1 | 1996 | 27 | 0.040 |
Why?
|
| Vaginal Smears | 1 | 2017 | 68 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 1997 | 234 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 737 | 0.040 |
Why?
|
| Dependovirus | 1 | 2016 | 34 | 0.040 |
Why?
|
| PAX8 Transcription Factor | 2 | 2007 | 23 | 0.040 |
Why?
|
| Cystectomy | 1 | 1997 | 102 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1655 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 1999 | 238 | 0.040 |
Why?
|
| Down-Regulation | 3 | 2003 | 508 | 0.040 |
Why?
|
| Valine | 1 | 1996 | 62 | 0.040 |
Why?
|
| Ureter | 1 | 1997 | 92 | 0.040 |
Why?
|
| Mass Screening | 1 | 2001 | 601 | 0.040 |
Why?
|
| Patient Preference | 1 | 2017 | 104 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2017 | 153 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 2241 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 126 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1804 | 0.030 |
Why?
|
| Glycerol-3-Phosphate Dehydrogenase (NAD+) | 1 | 2015 | 3 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2001 | 929 | 0.030 |
Why?
|
| Self Care | 1 | 2017 | 162 | 0.030 |
Why?
|
| Drinking | 1 | 2015 | 33 | 0.030 |
Why?
|
| AIDS Dementia Complex | 1 | 1995 | 8 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2001 | 1121 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2015 | 101 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1997 | 302 | 0.030 |
Why?
|
| Logistic Models | 1 | 1999 | 1179 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2015 | 111 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2012 | 263 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1997 | 487 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2001 | 813 | 0.030 |
Why?
|
| Educational Status | 1 | 1995 | 190 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1995 | 35 | 0.030 |
Why?
|
| Stents | 1 | 1997 | 377 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2015 | 270 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2014 | 2 | 0.030 |
Why?
|
| Eating | 1 | 2015 | 165 | 0.030 |
Why?
|
| Financing, Government | 1 | 2014 | 23 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2016 | 343 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2007 | 135 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1994 | 157 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2007 | 298 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 292 | 0.030 |
Why?
|
| Psychological Tests | 1 | 1994 | 91 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 239 | 0.030 |
Why?
|
| Public Policy | 1 | 2014 | 52 | 0.030 |
Why?
|
| Proline | 1 | 1994 | 57 | 0.030 |
Why?
|
| Genome | 1 | 1997 | 372 | 0.030 |
Why?
|
| Cerebrum | 1 | 2013 | 15 | 0.030 |
Why?
|
| Amino Acid Transport System y+L | 1 | 2013 | 3 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 200 | 0.030 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2013 | 5 | 0.030 |
Why?
|
| Fusion Regulatory Protein 1, Light Chains | 1 | 2013 | 6 | 0.030 |
Why?
|
| Algorithms | 1 | 2002 | 1824 | 0.030 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2013 | 7 | 0.030 |
Why?
|
| Codon | 2 | 2009 | 124 | 0.030 |
Why?
|
| Serine | 1 | 1994 | 99 | 0.030 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Base Composition | 1 | 1993 | 35 | 0.030 |
Why?
|
| Gluconeogenesis | 1 | 2013 | 14 | 0.030 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2013 | 13 | 0.030 |
Why?
|
| Arginine | 2 | 2009 | 136 | 0.030 |
Why?
|
| Organic Anion Transporters | 1 | 2013 | 26 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 1993 | 23 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2014 | 121 | 0.030 |
Why?
|
| Body Composition | 1 | 2013 | 68 | 0.030 |
Why?
|
| Bangladesh | 1 | 2014 | 318 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1997 | 1696 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 148 | 0.030 |
Why?
|
| Compassionate Use Trials | 1 | 2012 | 8 | 0.030 |
Why?
|
| Urea | 1 | 2012 | 58 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 42 | 0.030 |
Why?
|
| Genes | 1 | 1993 | 305 | 0.030 |
Why?
|
| Polysomnography | 1 | 2013 | 151 | 0.030 |
Why?
|
| Triglycerides | 1 | 2013 | 230 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 372 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2013 | 135 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2012 | 6479 | 0.030 |
Why?
|
| Diseases in Twins | 1 | 2012 | 65 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 149 | 0.030 |
Why?
|
| Leucine | 1 | 1992 | 67 | 0.030 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1992 | 53 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 2012 | 86 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2012 | 44 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2013 | 169 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2012 | 87 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 646 | 0.030 |
Why?
|
| Ligands | 2 | 2003 | 433 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 850 | 0.020 |
Why?
|
| Cell Line | 2 | 2010 | 2474 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 1990 | 20 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2013 | 373 | 0.020 |
Why?
|
| Child Development | 1 | 2012 | 163 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 2438 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 94 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 277 | 0.020 |
Why?
|
| Tretinoin | 1 | 1991 | 126 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1992 | 164 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 171 | 0.020 |
Why?
|
| Sleep, REM | 1 | 2010 | 50 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1218 | 0.020 |
Why?
|
| Sleep Stages | 1 | 2010 | 45 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 1018 | 0.020 |
Why?
|
| Postoperative Complications | 3 | 2012 | 2204 | 0.020 |
Why?
|
| Ileum | 2 | 2001 | 159 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 121 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2010 | 167 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2213 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 3639 | 0.020 |
Why?
|
| Ghana | 1 | 2009 | 4 | 0.020 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2013 | 212 | 0.020 |
Why?
|
| Hematopoiesis | 2 | 1981 | 164 | 0.020 |
Why?
|
| Cell Division | 2 | 1981 | 693 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 1997 | 1465 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 287 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2010 | 127 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 493 | 0.020 |
Why?
|
| Methylation | 1 | 2010 | 251 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 378 | 0.020 |
Why?
|
| Codon, Terminator | 2 | 1999 | 21 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1378 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 593 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2012 | 831 | 0.020 |
Why?
|
| Trinidad and Tobago | 1 | 2008 | 4 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1015 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1992 | 383 | 0.020 |
Why?
|
| Histones | 1 | 2010 | 311 | 0.020 |
Why?
|
| Calcification, Physiologic | 1 | 2007 | 33 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2007 | 24 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2007 | 34 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2702 | 0.020 |
Why?
|
| Chromatin | 1 | 2010 | 384 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 1991 | 380 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1313 | 0.020 |
Why?
|
| Uracil | 1 | 2007 | 56 | 0.020 |
Why?
|
| Puberty, Precocious | 1 | 2007 | 36 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 2738 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 318 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1992 | 1928 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2007 | 200 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2007 | 158 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 1986 | 144 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2006 | 147 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1462 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1776 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2006 | 121 | 0.020 |
Why?
|
| Bone Density | 1 | 2007 | 208 | 0.020 |
Why?
|
| Turkey | 1 | 2005 | 20 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1986 | 347 | 0.020 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2005 | 33 | 0.020 |
Why?
|
| Siblings | 1 | 2005 | 111 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 1998 | 206 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 280 | 0.020 |
Why?
|
| Thermogenesis | 1 | 2005 | 34 | 0.020 |
Why?
|
| Acclimatization | 1 | 2005 | 76 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2005 | 157 | 0.020 |
Why?
|
| Azores | 1 | 2004 | 3 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2005 | 165 | 0.020 |
Why?
|
| DNA Repair | 1 | 2007 | 356 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 330 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2005 | 309 | 0.020 |
Why?
|
| Dimerization | 1 | 2004 | 143 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 239 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 991 | 0.010 |
Why?
|
| Temperature | 1 | 2005 | 396 | 0.010 |
Why?
|
| Liver Neoplasms | 2 | 2004 | 737 | 0.010 |
Why?
|
| Wakefulness | 1 | 2004 | 134 | 0.010 |
Why?
|
| Fetal Resorption | 1 | 2003 | 2 | 0.010 |
Why?
|
| Freund's Adjuvant | 1 | 2003 | 26 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2004 | 332 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2005 | 227 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2003 | 245 | 0.010 |
Why?
|
| Immunization | 1 | 2003 | 159 | 0.010 |
Why?
|
| Rats, Zucker | 1 | 2002 | 38 | 0.010 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2002 | 15 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 1604 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 2002 | 39 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2002 | 28 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 3264 | 0.010 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2003 | 368 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 258 | 0.010 |
Why?
|
| Growth Hormone | 1 | 2002 | 97 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1981 | 33 | 0.010 |
Why?
|
| Glucuronidase | 1 | 1981 | 20 | 0.010 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2001 | 17 | 0.010 |
Why?
|
| Hypothermia | 1 | 2001 | 26 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2001 | 72 | 0.010 |
Why?
|
| Deafness | 1 | 2001 | 47 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2001 | 64 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2005 | 1286 | 0.010 |
Why?
|
| Calcium Chloride | 1 | 1981 | 9 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2001 | 87 | 0.010 |
Why?
|
| HIV | 1 | 2001 | 47 | 0.010 |
Why?
|
| Thymidine | 1 | 1981 | 59 | 0.010 |
Why?
|
| Movement Disorders | 1 | 2001 | 44 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2001 | 100 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 303 | 0.010 |
Why?
|
| Switzerland | 1 | 2000 | 17 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2004 | 386 | 0.010 |
Why?
|
| Proteoglycans | 1 | 1981 | 122 | 0.010 |
Why?
|
| Gelatin | 1 | 1980 | 25 | 0.010 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2001 | 241 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 526 | 0.010 |
Why?
|
| Feedback | 1 | 2001 | 132 | 0.010 |
Why?
|
| DNA Replication | 1 | 1981 | 164 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2000 | 90 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2001 | 498 | 0.010 |
Why?
|
| Receptors, Corticotropin | 1 | 1999 | 5 | 0.010 |
Why?
|
| Osteocytes | 1 | 1979 | 9 | 0.010 |
Why?
|
| Goldfish | 1 | 1979 | 6 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1999 | 63 | 0.010 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2000 | 28 | 0.010 |
Why?
|
| Primates | 1 | 2001 | 151 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2002 | 263 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1980 | 318 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1981 | 424 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2000 | 476 | 0.010 |
Why?
|
| Reference Standards | 1 | 1999 | 143 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2001 | 302 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 2433 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1998 | 67 | 0.010 |
Why?
|
| Antibodies | 1 | 1981 | 353 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 680 | 0.010 |
Why?
|
| DNA, Antisense | 1 | 1998 | 15 | 0.010 |
Why?
|
| Endocrine Glands | 1 | 1997 | 13 | 0.010 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 1998 | 41 | 0.010 |
Why?
|
| Xenopus | 1 | 1998 | 125 | 0.010 |
Why?
|
| Fishes | 1 | 1979 | 137 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 1998 | 169 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2000 | 881 | 0.010 |
Why?
|
| Nerve Net | 1 | 2001 | 366 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 1997 | 147 | 0.010 |
Why?
|
| Cosyntropin | 1 | 1996 | 5 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2000 | 666 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 1351 | 0.010 |
Why?
|
| Epilepsy | 1 | 2001 | 397 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1998 | 142 | 0.010 |
Why?
|
| Calcium | 1 | 1981 | 1152 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1997 | 221 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 560 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1995 | 39 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1998 | 465 | 0.010 |
Why?
|
| Phylogeny | 1 | 2001 | 1137 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1995 | 146 | 0.010 |
Why?
|
| Personality Assessment | 1 | 1995 | 98 | 0.010 |
Why?
|
| Intelligence | 1 | 1995 | 71 | 0.010 |
Why?
|
| Child Behavior Disorders | 1 | 1995 | 76 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 898 | 0.010 |
Why?
|
| Histidine | 1 | 1994 | 55 | 0.010 |
Why?
|
| Prostatectomy | 1 | 1997 | 471 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 1379 | 0.010 |
Why?
|
| RNA | 1 | 1998 | 560 | 0.010 |
Why?
|
| Hepatoblastoma | 1 | 1993 | 12 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 1993 | 30 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 1993 | 34 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1993 | 64 | 0.010 |
Why?
|
| Niacin | 1 | 1993 | 37 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 137 | 0.010 |
Why?
|
| CHO Cells | 1 | 1993 | 187 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 1993 | 80 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1993 | 68 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1993 | 148 | 0.010 |
Why?
|
| Cricetinae | 1 | 1993 | 560 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 268 | 0.010 |
Why?
|
| Laminin | 1 | 1992 | 85 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1992 | 131 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1993 | 326 | 0.010 |
Why?
|
| Binding Sites | 1 | 1993 | 1104 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1992 | 552 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1992 | 791 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 1993 | 534 | 0.010 |
Why?
|
| Cell Movement | 1 | 1992 | 764 | 0.010 |
Why?
|